KLRC1 and neoplasm: As IL-2Rγ usually co-exists with IL-2Rβ in immune cells, these results suggested that NKG2A with relative narrow expression profile might serve as a novel target for the delivery of IL-2Rβγ agonist, which might carry a lower risk to induce Tregs-mediated immunosuppression for human tumor immunotherapy.